GeneDx Appoints Everett Cunningham as CEO to Lead Next Phase of Genomic Diagnostics Growth
19 hours ago
1 min read
Gaithersburg, MD, November 18, 2026 (Business Wire) -- GeneDx Holdings Corp. (NASDAQ: WGS), a genomics company specializing in rare disease diagnosis and genomic testing, has appointed Everett Cunningham as Chief Executive Officer and a member of its Board of Directors, effective on or before December 15, 2026. Cunningham will succeed Katherine Stueland, who will step down as CEO and board member when he assumes the role and remain with the company as an advisor through January 31, 2027, to support the leadership transition. Cunningham brings more than 35 years of experience across diagnostics, genomics, medical technology, and pharmaceuticals. He most recently served as President and CEO of Quanterix Corporation and previously held senior leadership positions at Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer.
Read full article here.






















Comments